Chemours (CC) Expected to Release Earnings on Tuesday

Chemours (NYSE:CC) is projected to issue its Q2 2026 results after the market closes on Tuesday, August 4th. Analysts expect the company to announce earnings of $0.4964 per share and revenue of $1.6545 billion for the quarter. Parties can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 8:00 AM ET.

Chemours (NYSE:CC) last announced its quarterly earnings results on Tuesday, May 5th. The specialty chemicals company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.10. Chemours had a negative net margin of 6.82% and a positive return on equity of 52.49%. The firm had revenue of $1.38 billion during the quarter, compared to analyst estimates of $1.40 billion. During the same period in the previous year, the business posted $0.13 earnings per share. The business’s revenue for the quarter was up 1.0% on a year-over-year basis. On average, analysts expect Chemours to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Chemours Stock Performance

Shares of CC traded down $0.12 during trading hours on Tuesday, hitting $16.86. The stock had a trading volume of 176,321 shares, compared to its average volume of 3,043,907. The firm has a market capitalization of $2.54 billion, a PE ratio of -6.38 and a beta of 1.41. The company has a debt-to-equity ratio of 18.98, a current ratio of 1.82 and a quick ratio of 0.87. The stock has a fifty day moving average price of $20.23 and a 200 day moving average price of $19.95. Chemours has a 12 month low of $10.44 and a 12 month high of $28.67.

Chemours Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 16th. Stockholders of record on Sunday, May 17th were paid a $0.0875 dividend. This represents a $0.35 annualized dividend and a dividend yield of 2.1%. The ex-dividend date was Friday, May 15th. Chemours’s dividend payout ratio is -13.26%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on CC shares. Zacks Research raised shares of Chemours from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 21st. Royal Bank Of Canada lifted their target price on shares of Chemours from $26.00 to $29.00 and gave the company an “outperform” rating in a research note on Monday, May 11th. JPMorgan Chase & Co. increased their price target on Chemours from $17.00 to $22.00 and gave the stock a “neutral” rating in a research note on Thursday, May 21st. Alembic Global Advisors reaffirmed an “overweight” rating and issued a $30.00 price objective on shares of Chemours in a research note on Wednesday, May 13th. Finally, Truist Financial boosted their price objective on Chemours from $27.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, April 28th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $24.10.

Institutional Trading of Chemours

A number of hedge funds have recently added to or reduced their stakes in CC. Corient Private Wealth LLC raised its holdings in Chemours by 62.3% in the 4th quarter. Corient Private Wealth LLC now owns 31,399 shares of the specialty chemicals company’s stock worth $370,000 after purchasing an additional 12,047 shares during the period. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Chemours in the fourth quarter valued at about $191,000. McMillan Office Inc. purchased a new position in Chemours in the fourth quarter worth approximately $173,000. AQR Capital Management LLC purchased a new stake in shares of Chemours in the 1st quarter valued at approximately $161,000. Finally, iSAM Funds UK Ltd boosted its position in shares of Chemours by 66.8% during the fourth quarter. iSAM Funds UK Ltd now owns 13,466 shares of the specialty chemicals company’s stock worth $159,000 after buying an additional 5,394 shares during the period. 76.26% of the stock is owned by hedge funds and other institutional investors.

Chemours Company Profile

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.